AngioDynamics, Inc. (NASDAQ:ANGO) has received an average rating of “Hold” from the six analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $21.33.
Several research firms recently commented on ANGO. TheStreet cut AngioDynamics from a “c” rating to a “d+” rating in a research note on Thursday, October 3rd. BidaskClub cut AngioDynamics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 8th. KeyCorp decreased their target price on AngioDynamics from $30.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 4th. Finally, ValuEngine raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st.
Shares of ANGO stock traded down $0.35 on Friday, hitting $15.09. The company had a trading volume of 183,800 shares, compared to its average volume of 234,990. The firm has a market cap of $568.44 million, a P/E ratio of 18.18 and a beta of 0.63. The stock’s 50-day moving average is $15.12 and its two-hundred day moving average is $18.45. AngioDynamics has a twelve month low of $13.72 and a twelve month high of $25.48.
In other AngioDynamics news, CEO James C. Clemmer bought 15,000 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The stock was acquired at an average price of $14.19 per share, with a total value of $212,850.00. Following the completion of the purchase, the chief executive officer now directly owns 260,418 shares of the company’s stock, valued at approximately $3,695,331.42. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. bought a new position in AngioDynamics in the second quarter worth approximately $33,000. Venturi Wealth Management LLC bought a new position in AngioDynamics in the third quarter worth approximately $34,000. Nisa Investment Advisors LLC boosted its holdings in AngioDynamics by 100.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock worth $43,000 after acquiring an additional 1,100 shares in the last quarter. Bank of Montreal Can boosted its holdings in AngioDynamics by 78.7% in the second quarter. Bank of Montreal Can now owns 6,981 shares of the medical instruments supplier’s stock worth $138,000 after acquiring an additional 3,075 shares in the last quarter. Finally, Pacer Advisors Inc. bought a new position in AngioDynamics in the third quarter worth approximately $141,000. 99.50% of the stock is owned by institutional investors and hedge funds.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: How Do You Make Money With Penny Stocks?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.